Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4621 to 4635 of 8238 results

  1. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    Recommendation ID CG146/4 Question Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of

    Research recommendation
    Published
    9 June 2015

  2. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    Recommendation ID NG132/1 Question What is the clinical utility of bone turnover markers in the diagnosis and management of primary...

    Research recommendation
    Published
    25 October 2019

  3. The effect of injectable contraceptives on bone mineral density in women who have used DMPA for longer than 2 years is uncertain. Adequately powered surveys or cross‑sectional studies are needed to examine the recovery of bone mineral density after discontinuation of DMPA after long‑term and very long‑term use. Studies are also needed to examine the risk of bone fractures in older women.

    Recommendation ID CG30/4 Question The effect of injectable contraceptives on bone mineral density in women who have used DMPA for longer

    Research recommendation
    Published
    25 October 2019

  4. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    Recommendation ID CG145/3 Question Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when

    Research recommendation
    Published
    9 June 2015

  5. Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore the procedure should only be used in the context of  research .

    Recommendation ID IPG652/1 Question Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe

    Research recommendation
    Published
    15 November 2019

  6. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    Recommendation ID NG134/4 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief

    Research recommendation
    Published
    25 October 2019

  7. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in

    Research recommendation
    Published
    14 November 2018

  8. Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for clinical trials of management of Lyme disease?

    Recommendation ID NG95/1 Question Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for

    Research recommendation
    Published
    21 November 2018

  9. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    Recommendation ID NG14/02 Question Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment

    Research recommendation
    Published
    4 August 2022

  10. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    Recommendation ID NG14/01 Question Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response

    Research recommendation
    Published
    4 August 2022

  11. Detection and management of respiratory disorders in primary and community care:- Can detection and management of respiratory disorders in adults with cerebral palsy be improved in primary and community care?

    Recommendation ID NG119/3 Question Detection and management of respiratory disorders in primary and community care:- Can detection and

    Research recommendation
    Published
    8 March 2019

  12. Can GP practices deliver effective and cost effective condom schemes to reduce STIs?: -Can condom schemes be effective and cost effective in GP practices to reduce STIs? Can they be delivered in ways that are acceptable to GPs and other practice staff? In addition, how can the impact of such schemes be maximised?

    Recommendation ID NG68/5 Question Can GP practices deliver effective and cost effective condom schemes to reduce STIs?: -Can condom schemes

    Research recommendation
    Published
    12 October 2018

  13. Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum antibiotic therapy, without adversely affecting outcomes?

    Recommendation ID CG191/4 Question Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum

    Research recommendation
    Published
    9 June 2015

  14. Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?

    Recommendation ID NG196/7 Question Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people

    Research recommendation
    Published
    10 August 2021

  15. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory

    Research recommendation
    Published
    9 June 2015